Dronedarone in high-risk permanent atrial fibrillation.

[1]  D. Atar,et al.  Dronedarone in high-risk permanent atrial fibrillation. , 2011, The New England journal of medicine.

[2]  S. Nattel Dronedarone in atrial fibrillation--Jekyll and Hyde? , 2011, The New England journal of medicine.

[3]  J. Veale,et al.  Kidney paired donation--the next step. , 2011, The New England journal of medicine.

[4]  S. Connolly,et al.  Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.

[5]  J. McMurray,et al.  Increased mortality after dronedarone therapy for severe heart failure. , 2008, The New England journal of medicine.

[6]  H. Pollard,et al.  Heart failure drug digitoxin induces calcium uptake into cells by forming transmembrane calcium channels , 2008, Proceedings of the National Academy of Sciences.

[7]  H M James Hung,et al.  Statistical Considerations for Testing Multiple Endpoints in Group Sequential or Adaptive Clinical Trials , 2007, Journal of biopharmaceutical statistics.

[8]  Silvia G. Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC , 2006 .

[9]  Harlan M Krumholz,et al.  Association of serum digoxin concentration and outcomes in patients with heart failure. , 2003, JAMA.

[10]  R. Falk,et al.  Positive atrial inotropic effect of dofetilide after cardioversion of atrial fibrillation or flutter. , 2000, The American journal of cardiology.

[11]  M. Di leo,et al.  Transesophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation. , 1999, The American journal of cardiology.

[12]  R. Falk,et al.  Aggravation of postcardioversion atrial dysfunction by sotalol. , 1995, Journal of the American College of Cardiology.